A reference SNP for a disease
Tag SNP

Kaplan meier plot
how long after administration does the therapeutic exert a measurable effect
Biodistribution
Modifier Gene for SMN1 mutation
SMN2
A receptor tyrosine kinase that activates KRAS
EGFR
An ASO treatment for Spinal Muscular Atrophy
Spinraza
Explain a swim plot in terms of Casgevy
Each row is a person, they are treated and tracked (Hospitalizations for casgevy) depending on the disease
the pattern of distribution of a substance, often a therapeutic agent or drug, within a living organism after administration
Pharmacodynamics
●a research method that compares the genomes of many people to find genetic variations associated with specific diseases or traits
GWAS (genome wide association study)
GLP1 binds to this type of receptor
GPCR
Worst Isoform of ApoE
4
Improves stability and prevents degradation of ASO
2-MOE
how does the human body interact with the therapeutic after its administration
Pharmacokinetics
Explain the ASO Mechanism of Action
Rnase H
Explain siRNA mediated degradation
DSRNA, DICER, RISC Complex
The date of your next midterm
10/29
Explain a microwalk assay and how it pertains to SMA
ASOs "walked" across this region of the RNA to identify the positional effects of specific nucleotides on the splicing of exon 7. The purpose was to precisely map which intronic positions influence exon 7 inclusion or skipping, as skipping of exon 7 in SMN2 leads to reduced functional SMN protein and causes SMA.
a predefined outcome or event that is used to objectively measure the efficacy or safety of the therapeutic under investigation
Endpoint
regulates the splicing of the SMN gene's transcript, influencing exon 7 inclusion in the SMN protein
hnRNP
Make an antibody name 2 ways to make a humanized antibody
Transgenic mouse, phage display
Guiderna and TRACRrna, cas9, cut
Used to measure a child's motor function
Hine-2 Score
relationship between amount of therapeutic and some disease-relevant outcome
ligand independent dimerization
in T-cells, keeping
them in an inactive
state to limit possible
autoimmune
response, but also
limiting anti-tumor
response
CTLA4